Impact Factor
4.70
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
41.44
10,202 total citations
h5-index
133
h5 depth signal
Cited share
76.6%
200 of 261
Total citations
10,202
Citation footprint
Metric signal
32.90
External metric anchor
Self-citation
0.5%
46 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
559
United Kingdom
113
Canada
91
France
87
Germany
83
Citing Fields of Research
Oncology
595
Immunology
316
Lung Cancer
205
Breast Cancer
114
Immunotherapy
109
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,375
Articles tracked across the journal lifetime
Indexed publication set
261
200 cited publications
Last 12 months
130
10.8 publications/month
Open access share
5.4%
7 OA publications in the last year
Leading citing country
United States
559 citing publications
Leading citing field
Oncology
595 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v6n4, Apr. 2009-
v6n4, Apr. 2009-
Research Focus & Classification
Indexed Subjects
Oncology
Immunology
Lung Cancer
Liver & Colon Cancer
Breast Cancer
Lymphomas
Broad Categories
Neoplasms
Immunology
Lung Cancer
Lymphomas
Breast Cancer
Medical Ethics
Liver & Colon Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41571-026-01220-4
Open DOI
No cancer research without older adults, from prevention to end of life: a manifesto
02
03
DOI 10.1038/s41571-026-01213-3
Open DOI
A modular framework for antibody–drug conjugate biomarkers
The availability of approved antibody–drug conjugates (ADCs) has rapidly expanded across oncology indications, yet biomarker development remains dominated by semi-quantitative immunohistochemistry. Robust biomarkers are needed to improve...
04
DOI 10.1038/s41571-026-01215-1
Open DOI
Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma
05
DOI 10.1038/s41571-026-01211-5
Open DOI
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
06
DOI 10.1038/s41571-026-01201-7
Open DOI
Exercise therapy in cancer prevention and treatment
07
DOI 10.1038/s41571-026-01209-z
Open DOI
Exploring the immunological effects of antibody–drug conjugates
08
DOI 10.1038/s41571-026-01214-2
Open DOI
Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL
09
DOI 10.1038/s41571-026-01204-4
Open DOI
Optimizing the delivery of radiotherapy with artificial intelligence
Artificial intelligence (AI) and machine learning are transformative technologies that have sparked both excitement and concern. In radiation oncology, AI has been successfully applied to automate tasks, such as auto-contouring, geometri...
10
DOI 10.1038/s41571-026-01212-4
Open DOI
Tambotatug pelitecan — a potential new second-line treatment option for SCLC
Bibliographical & Catalog Notes
Description based on: Vol. 6, no. 5 (May 2009); title from cover.
Latest issue consulted: Vol. 6, no. 5 (May 2009).
Also issued online.